Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer

Qiu, Haibo

doi:10.1002/cac2.12019

Cited by 7 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toripalimab has been used to treat several kinds of unresectable or metastatic malignant tumors and the application of toripalimab in advanced NSCLC are increasingly reported. Preliminary data suggested that its safety and effectiveness were encouraging [7 – 10] . In particular, a recent single-center, open-label, parallel-control, phase 1 trial (NCT03301688) demonstrated the high security and exciting antitumor activity of toripalimab in patients with advanced NSCLC [2] .…”

Section: Discussionmentioning

confidence: 99%

Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report

Zhai

Che

et al. 2022

J Cardiothorac Surg

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors were used for patients with advanced non-small cell lung cancer (NSCLC) more and more frequently and the effects were thrilling. Toripalimab as a new immune checkpoint inhibitor has been shown to be effective in patients with advanced NSCLC. However, data regarding the safety and feasibility of surgical resection after treatment with toripalimab for NSCLC remain scarce. Here, we present a case with locally advanced NSCLC that received video-assisted thoracic surgery (VATS) lobectomy after treatment with toripalimab in combination with chemotherapy. Case presentation A 62-year-old male patient with a history of coronary artery stenting operation for two times was found a 3.4 × 3.2 cm cavity mass in the upper lobe of the left lung and enlarged left hilar and mediastinal lymph nodes. Pathological results identified squamous cell carcinoma. The patient was diagnosed with a locally advanced NSCLC and received VATS left upper lobectomy and lymph node dissection after neoadjuvant chemotherapy plus toripalimab for 3 cycles. The postoperative pathological results showed complete tumor remission. Short-term follow-up results were excellent, and long-term results remain to be revealed. Conclusions Our preliminary results showed that the use of neoadjuvant toripalimab and chemotherapy for the locally advanced NSCLC before surgical resection is safe and feasible.

show abstract

Section: Discussionmentioning

confidence: 99%

Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report

Zhai

Che

et al. 2022

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…Toripalimab has been used to treat several kinds of unresectable or metastatic malignant tumors and the application of toripalimab in advanced NSCLC are increasingly reported. Preliminary data suggested that its safety and effectiveness were encouraging [7][8][9][10] . In particular, a recent single-center, open-label, parallel-control, phase 1 trial (NCT03301688) demonstrated the high security and exciting antitumor activity of toripalimab in patients with advanced NSCLC 2 .…”

Section: Discussionmentioning

confidence: 99%

Initial Experience of Video-assisted Thoracic Surgery Lobectomy After Neoadjuvant Chemotherapy Plus Toripalimab in a Patient With Locally Advanced Non-small Cell Lung Cancer: A Case Report

Zhai

Che

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors were used for patients with advanced non-small cell lung cancer (NSCLC) more and more frequently and the effects were thrilling. Toripalimab as a new immune checkpoint inhibitor has been shown to be effective in patients with advanced NSCLC. However, data regarding the safety and feasibility of surgical resection after treatment with toripalimab for NSCLC remain scarce. Here, we present a case with locally advanced NSCLC that received video-assisted thoracic surgery (VATS) lobectomy after treatment with toripalimab in combination with chemotherapy. Case Presentation A 62-year-old male patient with a history of coronary artery stenting operation for two times was found a 3.4 × 3.2cm cavity mass in the upper lobe of the left lung and enlarged left hilar and mediastinal lymph nodes. Pathological results identified squamous cell carcinoma. The patient was diagnosed with a locally advanced NSCLC and received VATS left upper lobectomy and lymph node dissection after neoadjuvant chemotherapy plus toripalimab for 3 cycles. The postoperative pathological results showed complete tumor remission. Short-term follow-up results were excellent, and long-term results remain to be revealed. ConclusionsOur preliminary results showed that the use of neoadjuvant toripalimab and chemotherapy for the locally advanced NSCLC before surgical resection is safe and feasible.

show abstract

“…Immune and targeted therapies have increasingly become the most promising antitumor strategies in use. [2][3][4][5] Immunotherapy has shown satisfactory results in treating both gastric and bladder cancers, 6,7 and through the targeting of HER2, trastuzumab offers better progression-free (PFS) and overall (OS) survival for patients with HER2+ gastric cancers. 8,9 Many preclinical studies and clinical research efforts conducted in recent years have proven the utility of combining immune and targeted therapies, reporting improved therapeutic responses and prolonged survival times in patients with many types of cancers.…”

Section: Introductionmentioning

confidence: 99%

Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review

Tian

Zhu

Zhang

2021

OTT

View full text Add to dashboard Cite

Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clinical practice. When and how to effectively treat both tumors, without compounding adverse effects, must be addressed. Herein, we describe an elderly man who presented with both gastric cancer (HER2+) and bladder cancer. Due to enlarged and fused lymph nodal metastasis, he was illsuited for stomach resection. After transurethral resection of the bladder tumor, we administered both chemotherapy and the targeted agent trastuzumab. Gastric cancer showed partial response however bladder cancer recurred following two cycles of this regimen, the adverse effects were prohibitive, prompting refusal of further chemotherapy and radiotherapy. He then received the immune checkpoint inhibitor (ICI) nivolumab and trastuzumab in combination. This particular regimen successfully controlled both cancers and substantially improved the patient's quality of life. Its long-term use did not intensify adverse reactions, enabling a progression-free survival of 21 months to date. We have also reviewed other published clinical strategies applied in rare instances of multiple primary malignancies as a reference for treating such patients.

show abstract

Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer

Cited by 7 publications

References 15 publications

Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report

Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report

Initial Experience of Video-assisted Thoracic Surgery Lobectomy After Neoadjuvant Chemotherapy Plus Toripalimab in a Patient With Locally Advanced Non-small Cell Lung Cancer: A Case Report

Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review

Contact Info

Product

Resources

About